Small molecule · Inhibitor of epidermal growth factor receptor (EGFR)
Phase 1Most advanced trial
1Registered trials
What is ERAS-801?
ERAS-801 is an orally bioavailable, CNS-penetrating inhibitor that binds and inhibits EGFR, including EGFR amplifications driven by oncogenic variants and wildtype EGFR. It is designed to block EGFR-mediated signaling and is studied in glioblastoma multiforme, including EGFR-driven CNS tumors and CNS metastases.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule
Targets
epidermal growth factor receptor (EGFR)
Mechanism
Inhibitor of epidermal growth factor receptor (EGFR)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.